secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2026-06-03T20:57:09+00:00
Accession:  0001213900-26-064796
Event type: regulatory
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharmaceuticals Plans to Seek FDA Priority Review Voucher for Tafenoquine in Babesiosis
--------------------------------------------------------------------------------

- Company intends to apply for a Commissioner's National Priority Review Voucher if trial results support NDA submission by Q1 2028.
- Tafenoquine is being evaluated in a randomized, placebo-controlled trial for patients hospitalized with severe babesiosis.
- Application depends on interim or final analysis of the severe babesiosis trial supporting a New Drug Application.
- Disclosure is provided to inform investors of current development and regulatory plans, subject to forward-looking risks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390026064796/0001213900-26-064796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390026064796/ea0293532-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-064796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer